OP-3136

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameOP-3136
Drug Alias NameOP-3136
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone acetyltransferase KAT6A inhibitorsHistone acetyltransferase KAT6B inhibitors
TargetsHistone acetyltransferase KAT6AHistone acetyltransferase KAT6B
Therapy Area/IndicationsMetastatic breast cancerProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOlema Pharmaceuticals IncAurigene Oncology Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOlema Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A